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safety profile, especially with respect to intra‑
cranial hemorrhages. They are also more con‑
venient therapeutic agents. The 2016 Europe‑
an Society of Cardiology guidelines clearly favor 
DOACs over VKAs in patients with AF.1 Howev‑
er, DOAC therapy is also associated with bleed‑
ing complications. The aim of this paper was to 
provide recommendations for the management 
Introduction Direct oral anticoagulants (DOACs) 
such as apixaban, dabigatran, edoxaban, and ri‑
varoxaban are mainly used in the prevention of 
thromboembolic complications in patients with 
atrial fibrillation (AF) and in the treatment of ve‑
nous thromboembolism. As compared with vi‑
tamin K antagonists (VKAs), DOACs are char‑
acterized by at least similar efficacy and better 
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AbsTRACT
Direct oral anticoagulants (DOACs) such as apixaban, dabigatran, edoxaban, and rivaroxaban are mainly 
used in the prevention of thromboembolic complications in patients with atrial fibrillation (AF) and in 
the treatment of venous thromboembolism. As compared with vitamin K antagonists (VKAs), they are 
characterized by at least similar efficacy and better safety profiles, especially with respect to intracranial 
hemorrhages. Moreover, they are more convenient therapeutic agents. The 2016 European Society of 
Cardiology guidelines clearly favor DOACs over VKAs in patients with AF. However, DOAC therapy is 
also associated with the risk of bleeding complications. The aim of this review was to provide recom‑
mendations for the management of bleeding complications during DOAC therapy in the Polish setting. 
The recommendations were based on the most important documents concerning this issue and were 
developed by representatives of different medical specialties. Experience in managing cases of bleeding 
on DOAC therapy is still limited. Therefore, we hope that this publication will be helpful in everyday clini‑
cal practice and that it will be useful for developing in ‑hospital recommendations for the management 
of patients with DOAC ‑related bleeding.
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bleeding risk factors and assessment of bleeding 
risk in patients on anticoagulation Risk factors for 
bleeding include modifiable risk factors, abnor‑
mal laboratory test results, and clinical risk fac‑
tors (Supplementary material online, Table S1).1 
Bleeding risk is assessed using scores developed 
mainly with the aim to support decisions on dos‑
ing in patients on anticoagulant therapy (Sup‑
plementary material online, Table S1). The most 
common score, HAS ‑BLED, has been developed 
on the basis of data from VKA ‑treated patients.8 
According to the HAS ‑BLED score, the annual 
bleeding risk ranges from 0.6% to 19.6%. How‑
ever, the use of this score in patients treated with 
DOACs is disputable, and other scores have been 
suggested for use in this patient group.9
As for surgery ‑associated bleeding risk, 3 cate‑
gories of procedures associated with various lev‑
els of perioperative bleeding risk can be distin‑
guished: minimal, low, and high (TAbLE 1). Periop‑
erative management is discussed in the “Urgent 
surgery” section.
direct oral anticoagulants DOACs directly and 
specifically inhibit one coagulation factor. They 
belong to 2 drug classes: direct thrombin inhib‑
itors (dabigatran) or direct factor Xa inhibitors 
(apixaban, edoxaban, and rivaroxaban). Full anti‑
coagulant effect is achieved after approximately 2 
to 3 hours from DOAC administration. The drugs 
differ in the extent of renal elimination, which is 
important for invasive procedure planning. In pa‑
tients with significant renal impairment, antico‑
agulant effect may be largely extended due to pro‑
longed half ‑life of the drug, especially in patients 
treated with dabigatran. The half ‑lives of rivarox‑
aban, apixaban, and edoxaban are only minimal‑
ly prolonged in patients with end ‑stage renal dis‑
ease. The use of DOACs is contraindicated in pa‑
tients with serious renal impairment (estimated 
glomerular filtration rate <30 ml/min/1.73 m2).10
Identification of an anticoagulant effect of direct oral 
anticoagulants The effect of DOACs on the re‑
sults of coagulation assays is presented in TAbLE 2. 
The most characteristic feature is a significant pro‑
longation of thrombin time (TT) with dabigatran 
of bleeding complications or urgent or elective 
procedures during DOAC therapy in the Polish 
setting. The recommendations were based on 
the most important documents concerning this 
issue1‑5 and were developed by representatives 
of different medical specialties, including cardi‑
ologists, gastroenterologists, neurologists, anes‑
thesiologist, surgeons, orthopedic surgeons, and 
others. Our recommendations were adjusted to 
the Polish setting in terms of the availability of 
the drugs, their price, and summary of product 
characteristics which is obligatory in Poland. Our 
document is targeted at practitioners; therefore, 
it is brief and concise without unnecessary details.
bleeding severity assessment Bleeding is a highly 
dynamic complication and its consequences de‑
pend not only on the site of bleeding but also on 
the presence of concomitant diseases. Therefore, 
the assessment of bleeding severity requires an in‑
dividualized approach.7 As the basis for assess‑
ing bleeding severity, we recommend adopting 
the International Society of Thrombosis and Hae‑
mostasis criteria,4,6 which distinguish 3 groups 
of bleeding.
Life ‑threatening bleeding Life ‑threatening bleed‑
ing is major bleeding with a significant loss of 
blood and full or developing hemodynamic insta‑
bility or symptomatic bleeding affecting critical 
organs, such as intracranial, spinal cord, intraoc‑
ular, retroperitoneal, and intraarticular or intra‑
muscular bleeding with compartment syndrome.
Major or moderate bleeding Major or moderate 
bleeding encompasses major bleeding that does 
not cause serious hemodynamic disorders (eg, 
gastrointestinal [GI] bleeding with hemoglobin 
concentrations reduced by 2 g/dl, although with‑
out hemodynamic destabilization) and more se‑
vere minor bleeding (eg, with moderate blood 
loss, but below 2 g/dl).
Minor bleeding This category refers to bleeding 
of low intensity and not affecting critical organs, 
as well as not directly life ‑threatening as assessed 
by the physician.
TAbLE 1 Risk of procedure ‑associated bleeding (modified from Pernod et al)5
Two ‑day risk of major bleeding
High (≥2%) Low (<2%) Minimal
Epidural anesthesia, subarachnoid 
anesthesia, lumbar puncture; major 
surgeries: neurosurgical, cardiosurgical, 
thoracic, orthopedic, vascular; 
abdominal and oncological procedures; 
prostate resection, including 
transurethral; bladder surgery; liver, 
kidney, prostate, and bladder biopsy; 
lithotripsy; removal of colon polyps 
(especially of >2 cm in size); 
reconstructive plastic surgery; arterial 
puncture at noncompressible site
Arthroscopy, skin/lymph node 
biopsy, arm/shoulder/foot 
surgeries, endoscopic biopsy, 
hysterectomy, laparoscopic 
cholecystectomy, inguinal 
hernia repair, hemorrhoid 
removal, endoscopic biopsy, 
electrophysiology study/
ablation, pacemaker or 
implantable cardioverter‑ 
‑defibrillator implantation
Minor skin procedures (excision of 
squamous cell and basal cell 
carcinomas, moles), cataract 
surgery, most dental procedures 
(eg, uncomplicated extraction of 
1–3 teetha), coronary 
angiography, nonsurgical 
endoscopy
a The risk of bleeding associated with dental procedures is described in detail in Kardiol Pol.7
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acute blood loss of varied etiology.5,13 Addition‑
al management procedures depend on the type 
of anticoagulation. Management steps in DOAC‑
‑treated patients should include bleeding sever‑
ity assessment and, if relevant, stabilization of 
the patient’s condition.13 If possible, the admin‑
istered anticoagulant should be identified and 
its activity assessed. Medical history should be 
obtained from the patient or his or her family 
members regarding the type of an anticoagulant 
or other drugs potentially affecting hemostasis 
and the time of their administration, along with 
basic information on renal and hepatic function. 
Laboratory tests may be helpful in identifying 
the drug and assessing its anticoagulant effect 
(TAbLE 2). Moreover, a decision should be made 
as to whether to continue anticoagulation (and 
if yes, what type) or whether to reverse antico‑
agulation (and if yes, by which method). Gener‑
ally, in life‑threatening bleeding, anticoagulation 
should be at least temporarily stopped. If the de‑
cision is made to discontinue anticoagulation, 
the timing of and procedure for restarting anti‑
coagulation should be specified. These decisions 
influence bleeding severity, individual thrombo‑
embolic risk due to anticoagulation interruption, 
and the risk of recurrent bleeding on restarting 
anticoagulation.
Bleeding severity is not the only factor to be 
considered. In each patient, clinical status should 
be assessed, including arterial pressure, heart 
rate, and organ hypoperfusion. The following lab‑
oratory tests should be performed: peripheral 
blood count, creatinine concentration with esti‑
mated glomerular filtration rate (preferably with 
the Cockcroft–Gault formula), coagulation param‑
eters with at least APTT, PT, international nor‑
malized ratio, and TT assessment, and transam‑
inase activity. The site of bleeding has to be iden‑
tified and compression therapy applied, if possi‑
ble, or management procedures recommended 
in the particular clinical setting should be used.13 
Normal diuresis should be maintained.
(normal TT confirms that dabigatran is not pres‑
ent in the bloodstream). Direct factor Xa inhibi‑
tors do not have any effect on the TT assay. Pro‑
longation of the prothrombin time is most pro‑
nounced with rivaroxaban, and prolongation of 
activated partial thromboplastin time (APTT)—
with dabigatran (although the prolongation de‑
pends on the reagent used and on individual pa‑
tient characteristics). None of the coagulation 
screening assays can be used for laboratory mon‑
itoring of DOAC activity with the aim to adjust 
the dose to ensure that a therapeutic effect is ob‑
tained. However, the measurement of an antico‑
agulant effect of these drugs is helpful in patients 
who present with serious bleeding or who require 
urgent surgery or intervention. 
The coagulation screening assays do not pro‑
vide clear evidence that a DOAC concentration 
in a given patient is normal, as different results 
in various patients receiving the same dose of 
the same DOAC have been observed. TAbLE 2 lists 
laboratory tests that may be used for anticoagu‑
lation measurement. The results of these tests are 
better correlated with the anticoagulant effect of 
DOACs as compared with coagulation assays, but 
their availability is limited. Normal TT confirms 
that dabigatran is not present in blood, while 
normal APTT suggests, although does not fully 
confirm, a clinically insignificant effect of dabig‑
atran. More precise tests for dabigatran measure‑
ment, such as dilute TT and ecarin clotting time, 
are currently used only in highly specialized cen‑
ters. Direct factor Xa inhibitors cause a signifi‑
cant prolongation of the prothrombin time and 
no change in TT; they may slightly prolong APTT. 
An anti ‑Xa activity assay, performed differently 
for individual direct factor Xa inhibitors, is used 
for precise assessment of their concentrations.11,12 
However, since the therapeutic range of DOACs 
is largely unknown, dose adjustments are gener‑
ally not recommended.
Management of bleeding Bleeding in DOAC‑
‑treated patients should be managed according to 
the recommendations developed for patients after 
TAbLE 2 Effects of direct oral anticoagulants on the results of coagulation screening assays and laboratory tests used for monitoring of direct oral 
anticoagulant activity (based on Gosselin and Adcock)12
Coagulation test Dabigatran Apixaban Rivaroxaban Edoxaban Comments
Coagulation screening assays
PT –/↑ –/↑ ↑/↑↑ –/↑ Result depends on the reagent and individual 
variability.APTT ↑/↑↑ –/↑ –/↑ –/↑
TT ↑↑↑ – – – Very sensitive to dabigatran: no TT prolongation 
means lack of dabigatran in plasma.
Laboratory tests
dTT ↑↑ – – – Sensitive to dabigatran, insensitive to Xa inhibitors
ECT/ECA ↑↑ – – –
Anti ‑Xa activity – ↑↑ ↑↑ ↑↑ Sensitive to anti ‑Xa inhibitors, insensitive to 
dabigatran
Abbreviations: APTT, activated partial thromboplastin time; dTT, dilute thrombin time; ECA, ecarin chromogenic assay; ECT, ecarin clotting time; PT, 
prothrombin time; TT, thrombin time; ↑↑, significant prolongation; ↑↑↑, very significant prolongation; “–”, no change
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1 hour after dabigatran use, 10 to 20 minutes af‑
ter rivaroxaban use, and 2 to 6 hours after apixa‑
ban use, could be a potential method of reducing 
serum drug concentrations. However, consider‑
able amounts of charcoal (approximately 1 g/kg 
of body weight) are required to achieve a signifi‑
cant effect, and clinical evidence for its effective‑
ness is very limited. 
Importantly, patients with acute moderate or 
major bleeding should be treated in the inten‑
sive care setting and subjected to hemodynam‑
ic parameter monitoring. Diagnostic and thera‑
peutic procedures for a specific type of bleeding, 
such as gastroscopy in a patient with GI bleed‑
ing, should be considered.
Management of life ‑threatening bleeding Hemo‑
dynamic stabilization usually determines the fu‑
ture status of the patient.14 Treatment should be 
conducted in the intensive care setting, and vital 
signs monitoring is necessary. Early packed red 
blood cell transfusion to replenish blood loss is 
recommended. Management should be comple‑
mented with actions aimed at a rapid reversal 
of the DOAC effect. For dabigatran, an immedi‑
ate intravenous administration of idarucizum‑
ab, a specific antidote, is the option of choice 
(TAbLE 3). If idarucizumab is not readily available 
for a dabigatran ‑treated patient or if the patient 
receives another DOAC, the use of prothrom‑
bin complex concentrate (PCC) or activated PCC 
(aPCC) should be considered (TAbLE 3). An addi‑
tional option is the use of recombinant activat‑
ed factor VII. PCC contains coagulation factors II, 
VII, IX, and X, and lower amounts of inhibitory 
proteins C and S, with a small addition of hepa‑
rin, while aPCC contains both inactivated and ac‑
tivated factors II, VII, IX, and X. PCCs supplied 
by various manufacturers differ slightly with re‑
gards to the content of coagulation factors and 
coagulation factor inhibitors.
Antidotes to direct oral anticoagulants Currently, 
the only available antidote to DOACs is idaru‑
cizumab, a reversal agent for dabigatran. How‑
ever, studies are underway for an antidote to 
factor Xa inhibitors (andexanet alfa) and for 
Management of acute minor bleeding In this clin‑
ical setting, it is best to follow the strategy of 
watchful waiting. Control tests are recommend‑
ed. Previously undiagnosed exacerbation of re‑
nal dysfunction and anemia or thrombocytope‑
nia may impact further management. The drug 
half ‑life is short in patients with normal renal 
and liver function; therefore, supporting mea‑
sures and actions aimed at reversing anticoagu‑
lant effect are usually not necessary in these pa‑
tients. The half‑life of dabigatran is 12 to 15 hours, 
while that of Xa inhibitors, 9 to 11 hours. Typical‑
ly, it is sufficient to omit 1 or 2 DOAC doses. In 
a population at a very high thromboembolic risk, 
attempts should be made at maintaining antico‑
agulant therapy.
Management of acute major or moderate bleeding If 
acute major or moderate bleeding is not associat‑
ed with hemodynamic destabilization, fluid ther‑
apy and blood and blood product supplementa‑
tion should be considered. Transfusion intensity 
depends on the severity of bleeding. In patients 
with thrombocytopenia of less than 50 000/mm3, 
platelet concentrate should be administered to 
a target value of 100 000/mm3 or higher. Fresh 
frozen plasma transfusion should be considered, 
but only to replenish vascular bed on account 
of blood loss (at a dose of 10–20 ml/kg of body 
weight), because the concentration of coagula‑
tion factors in plasma products is too low to re‑
verse the anticoagulant effects of DOACs. Main‑
taining normal diuresis is important as DOACs 
are partly eliminated by the kidneys, and renal 
elimination is particularly important in the case 
of dabigatran. Renal replacement therapy may be 
used to increase the rate of dabigatran elimination 
due to its low protein ‑binding capacity; however, 
it is rarely used for technical reasons and owing 
to the availability of antidote.
As additional supportive treatment in the man‑
agement of bleeding complications, slow intrave‑
nous administration of tranexamic acid may be 
considered (2–4 g/d in 2–4 divided doses). In pa‑
tients with renal failure, dosing should be reduced 
depending on the serum creatinine concentration. 
Oral activated charcoal, administered preferably 
TAbLE 3 Characteristics of the available products used in life ‑threatening bleeding
Product Brand name Ingredients Dosing
Prothrombin complex 
concentrate
Beriplex Concentrate of coagulation factors II, VII, IX, X 
and coagulation inhibitors protein C and S
50 U/kg (+ 25 U/kg, if needed) IV
Octaplex Concentrate of coagulation factors II, VII, IX, X 
and coagulation inhibitors: proteins C and S
50 U/kg (+ 25 U/kg, if needed) IV
Prothromplex total NF Concentrate of coagulation factors II, VII, IX, X 
and protein C
50 U/kg (+ 25 U/kg, if needed) IV
Activated prothrombin 
complex concentrate
FEIBA NF Concentrate of inactivated and activated 
coagulation factors II, VII, IX, X
50 U/kg IV; max. 200 U/kg/d
Recombinant activated 
factor VII
NovoSeven Coagulation factor VIIa 90 µg/kg IV
Idarucizumab 
(monoclonal antibody)
PRAXBIND Idarucizumab 5 g IV via 2 consecutive infusions 
(2 × 2.5 g) lasting 5–10 minutes each, or 
as bolus injection
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part the recommendations for the management 
of other life ‑threatening bleeds (FIGURE 1).
Management aimed at reversing the antico‑
agulant effect depends on the patient’s clinical 
status and the timing of the last DOAC dose. In 
the case of intracranial hemorrhage in a patient 
treated with dabigatran, idarucizumab is recom‑
mended. It should be administered even if APTT 
or TT is only slightly prolonged. The second dose 
of idarucizumab may be considered, for exam‑
ple in the case of recurrent bleeding in a patient 
with prolonged APTT or TT. PCC or aPCC (TAbLE 3) 
should be used in dabigatran ‑treated patients 
who cannot be administered idarucizumab and 
in those with intracranial hemorrhage receiv‑
ing factor Xa inhibitors. There is no evidence for 
the beneficial effects of recombinant factor VIIa; 
therefore, its use in cases of intracranial hemor‑
rhage is not recommended.20
In patients with intracranial hemorrhage, in‑
cluding those taking DOACs, a surgery to remove 
hematoma and treat the source of hemorrhage 
may be necessary. Embolization or surgery of 
a bleeding vascular malformation and evacua‑
tion of intracerebral hematoma are interventions 
with proven therapeutic efficacy in cases of intra‑
cranial hemorrhage. In emergency situations re‑
quiring urgent intervention in DOAC ‑treated pa‑
tients, therapy with idarucizumab, aPCC, or PCC 
should be used to achieve normal anticoagulation 
(TAbLE 3).5 Surgery can be performed only when 
the anticoagulant effect of a DOAC has been re‑
versed or minimized. Idarucizumab causes an im‑
mediate and full reversal of dabigatran effects and 
enables an urgent procedure of intracranial hema‑
toma removal.15 The preparation for a surgical in‑
tervention in cases of intracranial hemorrhage is 
the same as for procedures associated with high 
bleeding risk (TAbLE 1). The time for discontinua‑
tion of DOACs depends on creatinine clearance. 
For dabigatran, if idarucizumab has not been ad‑
ministered, the time ranges from at least 48 to 
96 hours from the last dose intake, and for fac‑
tor Xa antagonists, it is at least 48 hours (Sup‑
plementary material online, Table S2).
Management of upper and lower gastrointestinal 
bleeding In clinical trials, a slightly higher rate 
of GI bleeds was observed during treatment with 
a universal antidote acting on DOACs, heparins, 
and fondaparinux (ciraparantag).
Idarucizumab is a humanized antibody frag‑
ment that binds to dabigatran with a more than 
350 ‑fold higher affinity than dabigatran does to 
thrombin, which immediately, strongly, specifi‑
cally, and permanently binds dabigatran circulat‑
ing in the blood and quickly neutralizes its anti‑
coagulant effects (TAbLE 3). The dabigatran–ida‑
rucizumab complex is eliminated by the kidneys 
within several hours. Dabigatran therapy may be 
restarted after 24 hours from antidote adminis‑
tration. The efficacy and safety of idarucizum‑
ab were demonstrated in a group of 90 patients 
with severe bleeding or who required urgent sur‑
gery or invasive procedures.15 Adverse reactions 
were observed in no more than 5% of the patients 
and included headache and hypokalemia. No pro‑
thrombotic effect of idarucizumab has been re‑
ported so far.15 Idarucizumab should be used in 
patients with life ‑threatening bleeding or before 
urgent major surgeries (TAbLE 4).16‑18
Andexanet alfa, an analogue of factor Xa, a po‑
tential antidote to rivaroxaban, apixaban, edoxa‑
ban, heparin, low ‑molecular ‑weight heparin, and 
fondaparinux, is currently under investigation. 
It is administered through a prolonged intrave‑
nous infusion and causes a significant decrease 
in blood anticoagulant concentration and rever‑
sal of anticoagulant effects. However, the drug 
has not yet been approved for clinical use. More‑
over, some rare thrombotic events following its 
use have also been reported.17 
Management of intracranial bleeding Intracrani‑
al hemorrhages (ie, intracerebral hemorrhages, 
subdural hematoma, epidural hematoma, and 
subarachnoid hemorrhage) are rare, but life‑
‑threatening, bleedings.4 Their incidence is 50% 
lower in DOAC ‑treated patients than in patients 
receiving VKAs.2,19 Immediate drug discontinua‑
tion is the fundamental approach to intracranial 
hemorrhage management. In each case, it is nec‑
essary to record previous anticoagulant dosing 
and the timing of the last dose, as well as assess 
the anticoagulant effect and expected timing of 
coagulation status normalization (TAbLE 2). Drug 
therapy of all types of intracranial hemorrhages 
in patients receiving anticoagulants follows in 
TAbLE 4 Indications and contraindications to idarucizumab use
Indications
Life ‑threatening bleeding or bleeding affecting critical organs
Major bleeding despite local treatment or a high risk of bleeding recurrence due to dabigatran overdose or reduced 
elimination rate
Need of urgent surgery/intervention associated with a high risk of bleeding, which cannot be delayed
Contraindications
Treatment with an anticoagulant other than dabigatran, regardless of bleeding severity
Minor or major bleeding that can be managed with other methods (eg, gastrointestinal bleeding effectively controlled 
with endoscopic methods)
Elective surgeries, or surgery or intervention that can be delayed
High drug concentration or overdose with no signs of bleeding
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Urgent endoscopy in patients with upper GI 
bleeding should be performed after cardiovascu‑
lar stabilization. The next dose to be taken after 
the onset of bleeding symptoms should be omit‑
ted. In most cases, administration of prohemo‑
static agents is not justified. However, they should 
be considered in cases of massive, life ‑threatening 
bleeds or bleeds that cannot be controlled using 
endoscopic techniques (eg, bleeding associated 
with DOAC use and hemorrhagic gastritis). In 
the case of upper GI bleeding that requires sur‑
gery in a DOAC ‑treated patient, the decision on 
surgery should be made along with implement‑
ing procedures recommended in cases of urgent 
surgery in patients taking DOACs.23
It should be noted that diagnostic procedures 
of the upper and lower GI tract, including biop‑
sy, biliary and pancreatic stent (without simulta‑
neous sphincterotomy), and enteroscopy, are as‑
sociated with low or moderate bleeding risk. In 
other endoscopic procedures, the risk is consid‑
ered high.24 In the case of procedures at higher 
risk of bleeding, treatment should be discontin‑
ued (Supplementary material online, Table S2).
dabigatran (2 × 150 mg/d), rivaroxaban (1 × 20 
mg/d and 1 × 15 mg/d), and edoxaban, 1 × 60 mg/d, 
as compared with VKA therapy. In addition, dab‑
igatran at doses of 1 × 150 mg and 2 × 110 mg 
was associated with a higher rate of dyspeptic 
disorders.21
It is believed that antiplatelet or nonsteroi‑
dal anti ‑inflammatory drugs, esophagitis, and 
gastritis or gastroesophageal reflux requiring 
the use of proton pump inhibitors or histamine 
H2 ‑receptor antagonists increase the risk of GI 
bleeding. Bleeding in normal vessels in the lack 
of mucosal damage is rare. Therefore, Helicobacter 
pylori infection, history of peptic ulcer disease, 
concomitant steroid therapy, history of gastric 
and duodenal erosions, GI angiodysplasia, and 
diverticulosis are also important risk factors for 
GI bleeding. There are no effective methods for 
the prevention of lower GI bleeding.22 No stud‑
ies have convincingly justified prophylaxis with 
the use of proton pump inhibitors or precisely de‑
termined their doses, although it seems that their 
use should be recommended in DOAC ‑treated pa‑
tients at a high risk of upper GI bleeding.
FIGURE 1 Management of bleeding in patients on direct oral anticoagulants (modified from Heidbuchel et al3)
Abbreviations: DOAC, direct oral anticoagulant; eGFR, estimated glomerular filtration rate; FFP, fresh frozen plasma; INR, international normalized ratio; 
PRBC, packed red blood cell; rFVIIa, recombinant factor VIIa
• Hemodynamic status assessment (heart rate, arterial pressure, peripheral hypoperfusion, diuresis)
• Obtaining information on drugs and the timing of the last dose intake
• Blood count, transaminase, and renal function (creatinine, eGFR) tests
• Coagulation status assessment aimed at assaying APTT, TT, PT, INR (TAbLEs 1 and 3)
• Delay or omission of the next dose
• Review of concomitant medication
Consider:
• In dabigatran‑treated patients, 
administer idarucizumbab (5 g IV)
• PCC 50 U/kg +25 U/kg, if needed
• aPCC 50 U/kg; max. 200 U/kg/d
• rFVIIa (NovoSeven) 90 µg/kg
Life‑threatening bleedingMinor bleeding
bleeding in a doAC‑treated patient
Moderate or severe bleeding
symptomatic/supportive treatment:
• Compression of bleeding source
• Endoscopic management
• Surgical hemostasis
• Fluid therapy
• Blood components (PRBCs, FFP, platelet con‑
centrate) transfusion
• Oral activated charcoal (if the drug has been 
taken shortly before)
dabigatran:
• Maintain normal diuresis
• Consider hemodialysis
• Consider administration of idarucizumbab (5g IV)
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direct oral anticoagulants in primary prevention of ve‑
nous thromboembolism in patients after hip or knee 
surgery Usually, an epidural catheter is inserted 
or subarachnoid anesthesia is performed before 
hip or knee surgery. If the catheter is maintained 
in the perioperative period for analgesic therapy 
and DOACs at prophylactic doses (Supplementary 
material online, Table S3) are introduced, the re‑
moval of the epidural catheter may be safe pro‑
vided it is performed with appropriate delay af‑
ter the prophylactic therapy is stopped. Follow‑
ing catheter removal, safe DOAC therapy (if indi‑
cated) may be initiated after up to 10 to 20 hours 
(Supplementary material online, Table S3).24
orthopedic injury and trauma A significant per‑
centage of patients after orthopedic trauma are 
treated with DOACs for other reasons such as 
those related to internal diseases. Orthopedic 
procedures are usually elective, planned, and per‑
formed in patients who have discontinued DOACs 
in line with the recommendations for elective sur‑
geries (Supplementary material online, Table S4). 
However, posttraumatic patients on DOAC ther‑
apy often require urgent surgeries. In the first 
place, manual compression with the use of ban‑
dage or dressing is necessary to stop bleeding. If 
the wound is large and there are multiple sourc‑
es of bleeding, mechanical tamponade is indicat‑
ed until the anticoagulant effect is reversed. De‑
pending on bleeding severity, principles of man‑
agement presented in FIGURE 1 should be followed. 
Major surgeries should be avoided in the early 
posttraumatic period unless the patient had been 
treated with dabigatran and received idarucizum‑
ab. A broken leg or arm is usually managed using 
skeletal traction with ligamentotaxis, which does 
not generate additional bleeding risk. It is also 
necessary to assess risk factors for thrombosis 
and to implement preventive measures for venous 
thromboembolism, as well as ischemic stroke in 
patients with AF. Thromboembolic prophylaxis is 
implemented during the safe postoperative peri‑
od, that is, when hemostasis has been achieved.
bleeding in patients after coronary angioplasty who re‑
quire extended direct oral anticoagulant therapy In 
DOAC ‑treated patients undergoing coronary an‑
gioplasty, the radial artery should be the preferred 
vascular access to reduce the risk of perioperative 
bleeding.25 Long ‑term exposure of patients to tri‑
ple therapy with the use of 2 antiplatelet drugs 
and 1 anticoagulant drug is associated with an in‑
creased risk of bleeding. According to the Europe‑
an Society of Cardiology guidelines, the duration 
of triple therapy depends on whether the angio‑
plasty was elective or performed due to acute cor‑
onary syndrome (ACS) and on the risk of bleed‑
ing. Triple therapy after ACS should be main‑
tained for 6 months in patients at low bleeding 
risk as compared with the risk of thrombosis or 
another ACS. If the risk of bleeding is high as 
compared with the risk of thrombosis or another 
ACS, triple therapy should be administered only 
Even minor GI bleeding should be diagnosed. 
Diagnosis and removal of the cause of bleeding 
allow safe reinitiation of anticoagulation. In cas‑
es of prior life ‑threatening bleeding with no ev‑
ident cause, the decision to restart anticoagu‑
lant therapy is difficult and requires an individ‑
ualized approach. Of note, several analyses point 
to a lower risk of GI bleeding during treatment 
with dabigatran at a dose of 2 × 110 mg/d, apixa‑
ban at a dose of 2 × 2.5 mg/d, and edoxaban at a 
dose of 30 mg/d. Currently, it seems that these 
doses may be prescribed in patients with a his‑
tory of major GI bleeding.20,21
Neuraxial blockade (subarachnoid and epidural 
anesthesia) in patients on direct oral anticoagu‑
lants Neuraxial blockade (subarachnoid and 
epidural anesthesia) is a routine anesthesio‑
logic technique. Spinal cord hematoma is one 
of the most serious possible complications of 
this procedure. Anticoagulated patients are at a 
10 ‑fold higher risk of spinal cord hematoma dur‑
ing neuraxial blockade. Therefore, spinal anes‑
thesia should generally be avoided in patients 
taking rivaroxaban, apixaban, or edoxaban who 
require urgent surgery. However, it can be ap‑
plied in patients taking dabigatran, because 
its anticoagulant effect can be reversed with 
idarucizumab.
Neuraxial blockade in patients receiving 
DOACs should be discussed separately for 2 pop‑
ulations. The first population includes patients 
undergoing orthopedic surgery, who take DOACs 
at prophylactic doses to reduce the rate of throm‑
boembolic complications due to the surgery. For 
this indication, the use of DOACs is only tempo‑
rary and is initiated only after anesthesia and 
surgery. The second population includes patients 
who take DOACs for internal diseases, in whom 
neuraxial blockade may be applied because of 
surgery or analgesic interventions. When pre‑
paring for neuraxial blockade, an anesthesiolo‑
gist should particularly carefully weigh the ben‑
efits against the risks of the procedure, discuss 
this issue with the patient, and obtain his or her 
written consent.22,24
Neuraxial blockade performed to administer 
anesthesia for various procedures and manage 
pain not associated with surgery requires an in‑
dividualized approach in patients on DOACs. This 
approach should take into account the patient’s 
age, organ function (especially renal function), 
spinal degeneration, coagulopathies, concomitant 
medication, possible technical problems, and his‑
tory of regional anesthesia. DOAC discontinua‑
tion for at least 5 half ‑lives, like in the case of oth‑
er procedures at a high risk of bleeding, is recom‑
mended before neuraxial blockade. Before punc‑
ture, APTT and TT tests in dabigatran ‑treated 
patients and PT tests in rivaroxaban‑treated pa‑
tients are recommended. Suggested time to re‑
starting full anticoagulation after catheter re‑
moval varies between patients.22,24
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hemorrhage.1 In cases where the factor respon‑
sible for intracranial hemorrhage cannot be re‑
moved (eg, suspected amyloid angiopathy) or dual 
antiplatelet therapy is necessary, anticoagulation 
is contraindicated.1,3 Restarting oral anticoagula‑
tion is contraindicated in patients in whom bleed‑
ing occurred during treatment with appropriate 
doses of DOACs, during therapy interruption, or 
at nontherapeutic doses, in patients at older age, 
and in those with uncontrolled hypertension, cor‑
tical bleeding, major intracranial bleeding, numer‑
ous cerebral microbleeds on radiographic exami‑
nation, and in those with alcohol abuse.
Conclusions Experience in managing patients 
with bleeding episodes on DOAC therapy is still 
limited. Therefore, we hope that this paper will 
be helpful in everyday clinical practice and that it 
will be useful in developing in‑hospital manage‑
ment principles for this population of patients.
supplementary material online Supplementary 
material is available with the online version of 
the article at www.pamw.pl.
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